Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -290K | 0 | 0 | -6K | -61K |
| Operating Income | -11M | -8M | -6M | -2M | -2M |
| EBITDA | -12M | -8M | -4M | -4M | -1M |
| Net Income | -12M | -9M | -7M | -5M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$3.46
-20.82% today
1Y Change
-90.11%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is a Healthcare stock with listed on NASDAQ. The stock last traded around $3.46 and down 90.1% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +99.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +99.2%, free cash flow -29.4% with operating margin 0.0% and ROIC -460.8%. Stock Foundry combines SHPH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SHPH
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SHPH Max Drawdown
-92.73%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SHPH and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$1.2M
+76.9% YoY
Free Cash Flow
-$300.3K
+88.7% YoY
Revenue Growth
+0.0%
EPS Growth
+99.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -290K | 0 | 0 | -6K | -61K |
| Operating Income | -11M | -8M | -6M | -2M | -2M |
| EBITDA | -12M | -8M | -4M | -4M | -1M |
| Net Income | -12M | -9M | -7M | -5M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 334K | 2M | 3M | 8M | 505K |
| Total Assets | 10M | 3M | 6M | 9M | 652K |
| Total Liabilities | 8M | 2M | 2M | 976K | 2M |
| Shareholder Equity | 2M | 709K | 4M | 8M | -2M |
| Total Debt | 232K | 1M | 1M | 748K | 979K |
| Net Debt | -102K | -747K | -1M | -8M | 474K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
300K
+88.7% YoY
Capital Expenditures
0
Free Cash Flow
300K
+88.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-444.9%
Debt / Equity
0.10x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.